These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1494394)

  • 1. [15+/-deoxyspergualin, hope for patients with multiple sclerosis?].
    Kappos L; Theobald K; Hartung HP
    Nervenarzt; 1992 Dec; 63(12):768-71; discussion 772. PubMed ID: 1494394
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of 15-deoxyspergualin on mononuclear cells from kidney recipients.
    Johansson-Borg A; Ohlman S; Groth CG
    Transplant Proc; 1992 Feb; 24(1):267-8. PubMed ID: 1539276
    [No Abstract]   [Full Text] [Related]  

  • 3. Deoxyspergualin: mechanism of action and pharmacokinetics.
    Ramos EL; Nadler SG; Grasela DM; Kelley SL
    Transplant Proc; 1996 Apr; 28(2):873-5. PubMed ID: 8623442
    [No Abstract]   [Full Text] [Related]  

  • 4. FK506 and deoxyspergualin: experimental studies and clinical applications.
    Suzuki S
    Transpl Immunol; 1994 Sep; 2(3):190-8. PubMed ID: 7528087
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple sclerosis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring.
    Kappos L; Radü EW; Bernasconi L; Brunnschweiler H; Hartung HP; Haas J; Gehlen W; Hartard C; Lagreze HL; Rüttinger H
    Schweiz Arch Neurol Psychiatr (1985); 1993; 144(3):198-201. PubMed ID: 7687364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fingolimod].
    Hashi Y; Kondo T
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
    [No Abstract]   [Full Text] [Related]  

  • 8. Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis.
    Paghera S; Sottini A; Previcini V; Capra R; Imberti L
    Drugs Aging; 2020 Oct; 37(10):739-746. PubMed ID: 32761321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deoxyspergualin. Mechanism of action studies of a novel immunosuppressive drug.
    Tepper MA
    Ann N Y Acad Sci; 1993 Nov; 696():123-32. PubMed ID: 8109823
    [No Abstract]   [Full Text] [Related]  

  • 10. Establishment of rejection therapy with deoxyspergualin by multicentral controlled clinical studies in renal recipients.
    Amemiya H; Taguchi Y; Fukao K; Isono K; Omoto R; Ota K; Kosaki M; Takagi H; Oka T; Sonoda T
    Transplant Proc; 1993 Feb; 25(1 Pt 1):730-3. PubMed ID: 8438462
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
    Mitosek-Szewczyk K; Tabarkiewicz J; Wilczynska B; Lobejko K; Berbecki J; Nastaj M; Dworzanska E; Kolodziejczyk B; Stelmasiak Z; Rolinski J
    J Neurol Sci; 2013 Sep; 332(1-2):35-40. PubMed ID: 23835090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
    Weiner HL
    Arch Neurol; 2004 Oct; 61(10):1613-5. PubMed ID: 15477521
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple sclerosis: pathophysiology revisited.
    Sorensen PS
    Lancet Neurol; 2005 Jan; 4(1):9-10. PubMed ID: 15620850
    [No Abstract]   [Full Text] [Related]  

  • 16. Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients.
    Amemiya H; Suzuki S; Ota K; Takahashi K; Sonoda T; Ishibashi M; Omoto R; Koyama F; Orita K; Takagi H
    Int J Clin Pharmacol Res; 1991; 11(4):175-82. PubMed ID: 1813436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Japanese Collaborative Transplant Study Group of NKT-01.
    Amemiya H
    Transplant Proc; 1995 Feb; 27(1):31-2. PubMed ID: 7879015
    [No Abstract]   [Full Text] [Related]  

  • 18. T-lymphocyte subpopulations in multiple sclerosis--do they help to judge immunosuppressive therapy?
    Henneberg A; Fischer EG; Kornhuber HH
    Eur Arch Psychiatry Neurol Sci; 1988; 238(2):94-6. PubMed ID: 2850189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of 15-deoxyspergualin for treatment of acute graft rejection following renal transplantation.
    Suzuki S; Hayashi R; Kenmochi T; Shimatani K; Fukuoka T; Amemiya H
    Transplant Proc; 1990 Aug; 22(4):1615-7. PubMed ID: 2389422
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous administration of methyldeoxyspergualin prolongs xenograft survival in hamster-to-rat cardiac transplantation.
    Suzuki S; Nishimori H; Kido K; Arita S; Tashiro H; Ohdan H; Quiñones D; Amemiya H
    Transplant Proc; 1993 Feb; 25(1 Pt 1):430-1. PubMed ID: 8438365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.